Azitra, Inc. Receives NYSE American Non-Compliance Notice: Key Details for Investors
Azitra, Inc. Receives NYSE American Non-Compliance Notice and Issues Going Concern Disclosure
Key Points from the Report
- NYSE American Non-Compliance: Azitra, Inc. has received a formal notice from NYSE American LLC, indicating that the company is not in compliance with continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide. Specifically, Azitra’s stockholders’ equity has fallen below \$6 million while the company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.
- Previous Non-Compliance: Azitra had already received a letter on October 1, 2025, declaring non-compliance with Section 1003(a)(ii), which requires a minimum stockholders’ equity of \$4 million for companies with losses in three of the last four fiscal years.
- Compliance Plan Submission: On October 31, 2025, Azitra submitted a compliance plan to the NYSE American, outlining its strategy to regain compliance by April 1, 2027. The plan was formally accepted on December 16, 2025.
- Deadline for Compliance: Azitra has until April 1, 2027, to meet NYSE American’s minimum stockholders’ equity requirements. Failure to comply or demonstrate adequate progress may result in delisting proceedings.
- Continued Listing and Reviews: Azitra’s shares will continue to trade on NYSE American during the plan period, but the company will undergo periodic reviews, including quarterly compliance monitoring.
- Going Concern Disclosure: Azitra’s audited financial statements for the year ended December 31, 2025, include a “Substantial Doubt Regarding the Company’s Ability to Continue as a Going Concern” paragraph, as disclosed in its Annual Report on Form 10-K filed with the SEC.
- No Immediate Impact: Receipt of the NYSE American notice does not immediately affect the listing or trading of Azitra’s common stock, nor does it affect business operations or SEC reporting requirements.
- Funding Efforts: The company is actively exploring multiple funding avenues to restore compliance and sustain operations.
Potentially Price-Sensitive Information for Shareholders
- Risk of Delisting: If Azitra fails to regain compliance by April 1, 2027, or does not make sufficient progress according to the submitted plan, NYSE Regulation staff may initiate delisting proceedings. This is a critical risk for shareholders, as delisting can significantly impact liquidity and stock value.
- Going Concern Warning: The inclusion of a “Substantial Doubt Regarding the Company’s Ability to Continue as a Going Concern” in the audit opinion is a serious signal of financial distress. This could adversely affect investor confidence and share price.
- Funding Uncertainty: The company’s ability to secure new funding is crucial for compliance and its ongoing viability. Any failure to raise sufficient capital could result in worsened financial conditions.
- Operational Continuity: Despite the notices, Azitra’s operations and SEC reporting are not immediately affected, but this status could change subject to future developments.
Company Background and Pipeline Details
Azitra, Inc. is a clinical-stage biopharmaceutical company specializing in precision dermatology. Its lead program, ATR-12, utilizes an engineered strain of S. epidermidis to treat Netherton syndrome—a rare, chronic, and potentially fatal skin disease with no approved treatments. ATR-12 is currently in a Phase 1b clinical trial for adult patients.
Another advanced program, ATR-04, targets EGFR inhibitor-associated rash, impacting approximately 150,000 people in the US. ATR-04 has received FDA Fast Track designation and has an open IND for clinical trials.
Both programs are developed from Azitra’s proprietary platform, which features a microbial library of about 1,500 bacterial strains enhanced by AI and machine learning for drug candidate screening.
Forward-Looking Statements and Risks
The company has made several forward-looking statements, including its intent to comply with NYSE American’s requirements, secure additional funding, and continue development of its pipeline. These statements are subject to numerous risks and uncertainties, such as regulatory delays, ineffective product candidates, inaccurate market estimates, funding challenges, competitive threats, intellectual property disputes, personnel retention, and dependence on third parties for manufacturing and testing.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with financial advisors before making investment decisions. The content contains forward-looking statements subject to risks and uncertainties which may cause actual results to differ materially from those described. Azitra, Inc. may not update these statements except as required by law.
View Azitra, Inc. Historical chart here
